Cesar Libanati

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

Steven R. Cummings, Javier San Martín, Michael R. McClung et al. · New England Journal of Medicine · 2009 · 3.4K citations · Full text

Romosozumab Treatment in Postmenopausal Women with Osteoporosis

Felicia Cosman, Daria B. Crittenden, Jonathan D. Adachi et al. · New England Journal of Medicine · 2016 · 1.6K citations · Full text

Romosozumab in Postmenopausal Women with Low Bone Mineral Density

Michael R. McClung, Andreas Grauer, Steven Boonen et al. · New England Journal of Medicine · 2014 · 1.2K citations

Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial

Jacques P. Brown, Richard L. Prince, Chad Deal et al. · Journal of Bone and Mineral Research · 2008 · 595 citations

Total Hip, Gynecology, Pharmacotherapy +16

Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial

Bente Langdahl, Cesar Libanati, Daria B. Crittenden et al. · The Lancet · 2017 · 450 citations

Bone Disease, Sclerostin, Bone Health +7